ConductScience.org, home

Comparison · NCT02791763-1548cc3a

Daprodustat in ND Participants vs Epoetin Beta Pegol in ND Participants: Number of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Daprodustat in ND Participants vs Epoetin Beta Pegol in ND Participants: Number of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks. Trial comparisons, record NCT02791763-1548cc3a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02791763-1548cc3a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1570.1010.238wilson
Risk in group 20.1010.05730.172wilson
Risk difference, group 1 minus group 20.0565-0.03420.148newcombe hybrid score
Risk ratio, group 1 over group 21.560.7673.17log
Odds ratio, group 1 over group 21.660.743.74log
Number needed to treat, for one more participant with the outcome on Daprodustat in ND Participants than on Epoetin Beta Pegol in ND Participants17.7from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Daprodustat in ND ParticipantsEligible ND participants received oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 milligrams \[mg\] as recommended) dose once daily for 52 weeks.17108OG000
Group 2Epoetin Beta Pegol in ND ParticipantsEligible ND participants received subcutaneous (SC) epoetin beta pegol (25, 50, 75, 100, 150, 200 or 250 microgram \[µg\] as recommended) dose once every 2 or 4 weeks for 52 weeks.11109OG001

Outcome

Type
SECONDARY
Title
Number of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
Description
Number of ND participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.
Time frame
Up to week 52
Population
ITT Population

Source ClinicalTrials.gov

Trial

Title
Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia
NCT number
NCT02791763
Phases
PHASE3
Conditions
Anaemia
Interventions
1 to 4 mg tablets of GSK1278863, 6 mg GSK1278863 tablet, Epoetin beta pegol
Lead sponsor
GlaxoSmithKline
Results first posted
2019-11-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02791763-1548cc3a